Kangmei, Hengrui, Shanghai Pharmaceutical and other pharmaceutical enterprises have handed in their transcripts

After September, it's time for companies to disclose their performance statements As of October 29, according to incomplete statistics of local medical stations, 190 A-share listed pharmaceutical companies have disclosed the third quarter report of 2018 The net profit of 14 pharmaceutical enterprises is more than 2-digit From the perspective of the net profit of 190 pharmaceutical enterprises, the net profit of 14 pharmaceutical enterprises is more than 1 billion yuan, the highest one is Kangmei pharmaceutical industry of 3.847 billion yuan, followed by Shanghai Pharmaceutical (3.372 billion yuan), Hengrui Pharmaceutical (2.912 billion yuan), Yunnan Baiyao (2.732 billion yuan), XinHeCheng (2.537 billion yuan), international medicine (2.232 billion yuan), etc There are four loss making enterprises, among which Shanghai Laishi (- 1.293 billion yuan), Hengkang medical (- 387 million yuan), Jiuan medical (- 61 million yuan) and Shuangcheng Pharmaceutical (- 32 million yuan) are the second ones In terms of growth rate, there is one pharmaceutical enterprise with a net profit growth rate of more than 1000%, which is international medicine (1121.50%) In addition, there are 17 more than 100%, including Lexin medical (716.03%), Boji medicine (347.92%), Watson Biology (331.77%), Zhejiang medicine (291.39%), Zhifei Biology (280.95%), etc 49 companies saw a large decline in growth, including Hengkang medical (- 253.49%), Shanghai Laishi (- 237.51%), Shuangcheng Pharmaceutical (- 237.32%), unnamed Pharmaceutical (- 95.38%), guangshengtang (- 79.50%), Lizhu group (- 77.86%), etc.